Premium
WNK Signaling Inhibitors as Potential Antihypertensive Drugs
Author(s) -
AlAmri Mubarak A.,
Kadri Hachemi,
Dhiani Binar A.,
Mahmood Shumail,
Elzwawi Abdulrahman,
Mehellou Youcef
Publication year - 2017
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201700425
Subject(s) - druggability , signal transduction , computational biology , biology , bioinformatics , medicine , microbiology and biotechnology , genetics , gene
Since the discovery of WNK mutations that cause an inherited form of hypertension in humans, there has been increasing interest in targeting WNK signaling as a novel strategy for modulating blood pressure. This notion is now supported by numerous mouse models with impaired WNK signaling that exhibit reduced blood pressure. Biochemical analyses of the various protein components that make up this signaling pathway have identified a number of plausible molecular targets that are amenable to targeting by small molecules. To date, a selection of small‐molecule WNK signaling inhibitors have been identified and have shown promise in suppressing the activity of WNK signaling in cells and in animals. In this Minireview, we briefly discuss the WNK signaling pathway and provide an overview of the various druggable targets within this cascade, as well as the different WNK signaling inhibitors discovered to date.